| Diabetes Mellitus
Afrezza - (Insulin Human) Inhalation Powder vs Novolog
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Afrezza vs Insulin Diluting Medium For Novolog with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInsulin Diluting Medium For Novolog has a higher rate of injection site reactions vs Afrezza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Insulin Diluting Medium For Novolog but not Afrezza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afrezza
Insulin Diluting Medium For Novolog
At A Glance
Oral inhalation
At each meal
Rapid-acting insulin
SC injection
Pre-meal
Rapid-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Insulin-naive patients: 4 units inhaled at the beginning of each meal; patients switching from subcutaneous mealtime insulin convert per table (up to 3 units -> 4 units, 4-5 units -> 8 units, 6-7 units -> 12 units, >=8 units -> 16 units); adjust dose based on metabolic needs, blood glucose monitoring, and glycemic control goal.
Diabetes Mellitus Inject SC within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm; generally used with an intermediate- or long-acting insulin; may also be administered via continuous SC infusion pump or diluted to 0.05-1 unit/mL for IV infusion; individualize dose based on metabolic needs and blood glucose monitoring results.
Contraindications
- Episodes of hypoglycemia
- Chronic lung disease such as asthma or COPD due to risk of acute bronchospasm
- Previous severe hypersensitivity reaction to any regular human insulin product or any inactive ingredient in AFREZZA
- Episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or one of its excipients
Adverse Reactions
Most common (>=2%) Cough, throat pain or irritation, headache, diarrhea, productive cough, fatigue, nausea
Serious Acute bronchospasm, hypoglycemia, decline in pulmonary function, lung cancer, diabetic ketoacidosis, hypersensitivity reactions
Postmarketing Bronchospasm
Most common (>=5%) Headache, accidental injury, nausea, diarrhea (type 1 diabetes); hyporeflexia, onychomycosis, sensory disturbance, urinary tract infection, chest pain, skin disorder, abdominal pain, sinusitis (type 2 diabetes)
Serious Severe hypoglycemia, generalized allergy/anaphylaxis, hypokalemia, lipodystrophy, peripheral edema
Postmarketing Localized cutaneous amyloidosis at injection site, medication errors with insulin substitution, hyperglycemia or hypoglycemia associated with amyloidosis-related injection site changes
Pharmacology
Insulin lowers blood glucose in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; it also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Rapid-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with peak glucose-lowering effect 1-3 hours after SC injection and duration of action 3-5 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afrezza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Insulin Diluting Medium For Novolog
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Afrezza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Insulin Diluting Medium For Novolog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Afrezza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Insulin Diluting Medium For Novolog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$99/momo
Afrezza Patient Direct ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Insulin Diluting Medium For Novolog.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfrezzaView full Afrezza profile
Insulin Diluting Medium For NovologView full Insulin Diluting Medium For Novolog profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.